View ValuationSynBiotic 将来の成長Future 基準チェック /56SynBiotic利益と収益がそれぞれ年間72.4%と27.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-4.9% 76.1%なると予測されています。主要情報72.4%収益成長率76.09%EPS成長率Pharmaceuticals 収益成長23.9%収益成長率27.2%将来の株主資本利益率-4.90%アナリストカバレッジLow最終更新日19 Dec 2025今後の成長に関する最新情報Price Target Changed • Nov 27Price target decreased by 45% to €6.50Down from €11.80, the current price target is an average from 2 analysts. New target price is 224% above last closing price of €2.01. Stock is down 64% over the past year. The company is forecast to post a net loss per share of €0.33 next year compared to a net loss per share of €2.24 last year.Price Target Changed • Sep 08Price target decreased by 28% to €11.80Down from €16.30, the current price target is provided by 1 analyst. New target price is 297% above last closing price of €2.98. Stock is down 42% over the past year. The company is forecast to post a net loss per share of €0.44 next year compared to a net loss per share of €2.24 last year.Price Target Changed • Dec 27Price target decreased by 24% to €12.45Down from €16.30, the current price target is an average from 2 analysts. New target price is 183% above last closing price of €4.40. Stock is up 47% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €2.24 last year.Price Target Changed • Nov 20Price target decreased by 24% to €12.45Down from €16.30, the current price target is an average from 2 analysts. New target price is 123% above last closing price of €5.58. Stock is up 89% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €2.24 last year.Breakeven Date Change • May 31No longer forecast to breakevenThe analyst covering SynBiotic no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €50.0k in 2023. New forecast suggests the company will make a loss of €2.10m in 2023.Price Target Changed • Apr 13Price target increased by 28% to €75.00Up from €58.50, the current price target is provided by 1 analyst. New target price is 859% above last closing price of €7.82. Stock is down 58% over the past year. The company is forecast to post a net loss per share of €0.19 next year compared to a net loss per share of €4.15 last year.すべての更新を表示Recent updatesお知らせ • Mar 18SynBiotic SE, Annual General Meeting, Apr 23, 2026SynBiotic SE, Annual General Meeting, Apr 23, 2026, at 10:00 W. Europe Standard Time.Board Change • Mar 09No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • Feb 10No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • Jan 26No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Price Target Changed • Nov 27Price target decreased by 45% to €6.50Down from €11.80, the current price target is an average from 2 analysts. New target price is 224% above last closing price of €2.01. Stock is down 64% over the past year. The company is forecast to post a net loss per share of €0.33 next year compared to a net loss per share of €2.24 last year.Board Change • Nov 27No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • Sep 08No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Price Target Changed • Sep 08Price target decreased by 28% to €11.80Down from €16.30, the current price target is provided by 1 analyst. New target price is 297% above last closing price of €2.98. Stock is down 42% over the past year. The company is forecast to post a net loss per share of €0.44 next year compared to a net loss per share of €2.24 last year.New Risk • Jul 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€24.5m market cap, or US$28.8m).Board Change • Jun 18No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.お知らせ • Apr 19SynBiotic SE announced that it expects to receive €2.4 million in fundingSynBiotic SE announced a private placement that it will issue non-interest-bearing convertible bonds for the gross proceeds of up to €2,400,000 on April 17, 2025. The company will issue in several tranches of up to €200,000 each. The issue of the first convertible bonds is scheduled to start at the end of April 2025.New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Revenue is less than US$5m (€3.9m revenue, or US$4.4m). Market cap is less than US$100m (€21.2m market cap, or US$24.1m).Board Change • Mar 28No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Board Change • Feb 12No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Price Target Changed • Dec 27Price target decreased by 24% to €12.45Down from €16.30, the current price target is an average from 2 analysts. New target price is 183% above last closing price of €4.40. Stock is up 47% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €2.24 last year.Board Change • Dec 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Price Target Changed • Nov 20Price target decreased by 24% to €12.45Down from €16.30, the current price target is an average from 2 analysts. New target price is 123% above last closing price of €5.58. Stock is up 89% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €2.24 last year.Board Change • Nov 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman of Advisory Board Bruce Linton was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Aug 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.9m free cash flow). Earnings have declined by 49% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Revenue is less than US$5m (€4.1m revenue, or US$4.5m). Market cap is less than US$100m (€31.6m market cap, or US$35.1m).お知らせ • Aug 15SynBiotic SE, Annual General Meeting, Sep 20, 2024SynBiotic SE, Annual General Meeting, Sep 20, 2024, at 10:00 W. Europe Standard Time.New Risk • Aug 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (€34.5m market cap, or US$37.9m).New Risk • Jul 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Market cap is less than US$100m (€37.7m market cap, or US$40.4m).New Risk • Jun 21New major risk - Revenue and earnings growthRevenue has declined by 9.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 9.9% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (€35.6m market cap, or US$38.0m).New Risk • Mar 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (31% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€400k net loss in 2 years). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (€35.8m market cap, or US$39.2m).Board Change • Oct 11No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (4 non-independent directors). Chairman of the Board of Directors Sebastian Stietzel is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.New Risk • Jul 02New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Minor Risks Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (€21.1m market cap, or US$23.0m).Breakeven Date Change • May 31No longer forecast to breakevenThe analyst covering SynBiotic no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €50.0k in 2023. New forecast suggests the company will make a loss of €2.10m in 2023.Price Target Changed • Apr 13Price target increased by 28% to €75.00Up from €58.50, the current price target is provided by 1 analyst. New target price is 859% above last closing price of €7.82. Stock is down 58% over the past year. The company is forecast to post a net loss per share of €0.19 next year compared to a net loss per share of €4.15 last year.お知らせ • Nov 25SynBiotic SE Appoints Bruce Linton as Chairman of Newly Created Advisory BoardSynBiotic SE, accelerates implementation of the operational platform to achieve market leadership in the upcoming national legalization of recreational cannabis by securing Bruce Linton to its team. Mr. Linton is one of the most experienced and most successful cannabis entrepreneurs and investors globally and has been the driving force behind the creation of multiple global multi-billion dollar cannabis enterprises, several of them listed on NYSE, Nasdaq, TSX, TSX:V, CSE and ASX. Most notably, Mr. Linton is the founder and former Chairman and CEO of the global cannabis company Canopy Growth Corporation, which, at the time of his departure, had a market valuation of approximately CAD 20 billion and more than 25% market share in the Canadian recreational market while also being a global top tier supplier. Canopy was the first North American supplier to the German medical cannabis market. Combining unparalleled expertise in the areas of both medical and recreational cannabis, Mr. Linton is a powerful asset given SynBiotic's expansion plans, which cover both segments. Mr. Linton has been appointed as Chairman of SynBiotic's newly created Advisory Board and has invested capital in the company's most recent financing round. His investment plus options to buy further shares from existing shareholders will bring him to an ownership of approx. 5% in SynBiotic.Board Change • Nov 17No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Sep 02SynBiotic SE Launches Full-Line Medical Cannabis BrandSynBiotic SE launches full-line medical cannabis brand. In mid-September, the pharmacy market is due to attend Expopharm, the most important leading European trade fair. SynBiotic SE will present its new brand Hempamed Rx at its own booth. Europe's largest listed corporate group in the hemp and cannabis sector is launching an extensive range of full-spectrum extracts, dronabinol and various flowers. In this process, canna.sales GmbH becomes SynBiotic Sales GmbH, with a fifteen-person field sales team consisting of employees with many years of experience in the field of medical cannabis, and GECA Pharma GmbH, responsible for the import and distribution of medical cannabis products, becomes SynBiotic Distribution GmbH. Sales offensive in the field of medical cannabis: While other cannabis companies are downsizing their sales teams and seemingly fully concentrate on the legalization of recreational use, are keeping a firm eye on all areas of the existing and future cannabis market," says Lars Müller, CEO of SynBiotic SE. The goal: to provide competent advice throughout Germany. With the sales offensive, the Munich-based corporate group wants to underline its clear vision in the wake of increasing treatments and prescriptions for medical cannabis. Products from this area can be used to treat chronic pain, among other things. In particular, patients suffering from depression and anxiety/sleep disorders, but also Tourette's, MS or epilepsy, can alleviate their symptoms and the resulting pain through the use of medical cannabis. Strong pipeline: Unprecedented product innovations: SynBiotic SE will build up further capacities in the important field of medical cannabis and further expand its dominant position not only on the distribution side. The launch of Hempamed Rx also culminates years of research and development of innovative products that will be launched under the new brand in the coming weeks and months. Particularly in the field of medical cannabis, it is important to enable treatments that are optimally adapted to individual complaints. The dosage forms in particular make an important contribution to this. In order to enable everyone to benefit from the advantages of medical cannabis, SynBiotic SE is constantly expanding its product portfolio through the use of various carrier substances. The high bio-availability is as much in focus as the good tolerability of the products.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Breakeven Date Change • Aug 27Forecast to breakeven in 2022The analyst covering SynBiotic expects the company to break even for the first time. New forecast suggests the company will make a profit of €1.70m in 2022. Average annual earnings growth of 93% is required to achieve expected profit on schedule.Is New 90 Day High Low • Jan 11New 90-day high: €25.60The company is up 51% from its price of €17.00 on 13 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 10.0% over the same period.Is New 90 Day High Low • Dec 03New 90-day high: €20.20The company is up 13% from its price of €17.90 on 04 September 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.Is New 90 Day High Low • Nov 03New 90-day low: €13.90The company is down 15% from its price of €16.40 on 04 August 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period.Is New 90 Day High Low • Oct 08New 90-day low: €14.10The company is down 21% from its price of €17.90 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 8.0% over the same period.お知らせ • Oct 08SynBiotic SE (DUSE:L3D) acquired 25% stake in GreenLight Pharmaceuticals Ltd.SynBiotic SE (DUSE:L3D) acquired 25% stake in GreenLight Pharmaceuticals Ltd on October 6, 2020. In addition to the acquired share, SynBiotic also receives the option to strengthen its commitment in the future through further shares. SynBiotic SE (DUSE:L3D) completed the acquisition of 25% stake in GreenLight Pharmaceuticals Ltd on October 6, 2020.お知らせ • Sep 22SynBiotic SE (DUSE:L3D) entered into an agreement to acquire BioCBD E-commerce business of Umtr Group LimitedSynBiotic SE (DUSE:L3D) entered into an agreement to acquire BioCBD E-commerce business of Umtr Group Limited on September 21, 2020. Under the terms of transaction, certain tangible and intangible assets as well as the Umtr Group's customer base relating to BioCBD e-commerce are to be taken over by SynBiotic SE. The purchase price is to be paid partly in cash and partly in cash or in shares and comprises a total of a low single-digit million amount. Major part of purchase price can be paid in exchange for shares of SynBiotic.業績と収益の成長予測DUSE:SBX - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202724N/A00212/31/202619-1-10212/31/202516-2-1-1212/31/202416-2-3-3212/31/20234-11-3-3N/A12/31/20228-24-7-7N/A12/31/20219-13-6-5N/A12/31/20205-1-3-1N/A12/31/2019N/A000N/Aアナリストによる今後の成長予測収入対貯蓄率: SBXの予測収益成長率 (年間72.4% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: SBXの収益 ( 72.4% ) はGerman市場 ( 16.9% ) よりも速いペースで成長すると予測されています。高成長収益: SBXの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: SBXの収益 ( 27.2% ) German市場 ( 6.8% ) よりも速いペースで成長すると予測されています。高い収益成長: SBXの収益 ( 27.2% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SBX 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 18:45終値2026/03/09 00:00収益2023/12/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SynBiotic SE 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Harald Hofmwb research AGChristian SandherrNuWays AG
Price Target Changed • Nov 27Price target decreased by 45% to €6.50Down from €11.80, the current price target is an average from 2 analysts. New target price is 224% above last closing price of €2.01. Stock is down 64% over the past year. The company is forecast to post a net loss per share of €0.33 next year compared to a net loss per share of €2.24 last year.
Price Target Changed • Sep 08Price target decreased by 28% to €11.80Down from €16.30, the current price target is provided by 1 analyst. New target price is 297% above last closing price of €2.98. Stock is down 42% over the past year. The company is forecast to post a net loss per share of €0.44 next year compared to a net loss per share of €2.24 last year.
Price Target Changed • Dec 27Price target decreased by 24% to €12.45Down from €16.30, the current price target is an average from 2 analysts. New target price is 183% above last closing price of €4.40. Stock is up 47% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €2.24 last year.
Price Target Changed • Nov 20Price target decreased by 24% to €12.45Down from €16.30, the current price target is an average from 2 analysts. New target price is 123% above last closing price of €5.58. Stock is up 89% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €2.24 last year.
Breakeven Date Change • May 31No longer forecast to breakevenThe analyst covering SynBiotic no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €50.0k in 2023. New forecast suggests the company will make a loss of €2.10m in 2023.
Price Target Changed • Apr 13Price target increased by 28% to €75.00Up from €58.50, the current price target is provided by 1 analyst. New target price is 859% above last closing price of €7.82. Stock is down 58% over the past year. The company is forecast to post a net loss per share of €0.19 next year compared to a net loss per share of €4.15 last year.
お知らせ • Mar 18SynBiotic SE, Annual General Meeting, Apr 23, 2026SynBiotic SE, Annual General Meeting, Apr 23, 2026, at 10:00 W. Europe Standard Time.
Board Change • Mar 09No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • Feb 10No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • Jan 26No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Price Target Changed • Nov 27Price target decreased by 45% to €6.50Down from €11.80, the current price target is an average from 2 analysts. New target price is 224% above last closing price of €2.01. Stock is down 64% over the past year. The company is forecast to post a net loss per share of €0.33 next year compared to a net loss per share of €2.24 last year.
Board Change • Nov 27No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • Sep 08No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Price Target Changed • Sep 08Price target decreased by 28% to €11.80Down from €16.30, the current price target is provided by 1 analyst. New target price is 297% above last closing price of €2.98. Stock is down 42% over the past year. The company is forecast to post a net loss per share of €0.44 next year compared to a net loss per share of €2.24 last year.
New Risk • Jul 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€24.5m market cap, or US$28.8m).
Board Change • Jun 18No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
お知らせ • Apr 19SynBiotic SE announced that it expects to receive €2.4 million in fundingSynBiotic SE announced a private placement that it will issue non-interest-bearing convertible bonds for the gross proceeds of up to €2,400,000 on April 17, 2025. The company will issue in several tranches of up to €200,000 each. The issue of the first convertible bonds is scheduled to start at the end of April 2025.
New Risk • Apr 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Revenue is less than US$5m (€3.9m revenue, or US$4.4m). Market cap is less than US$100m (€21.2m market cap, or US$24.1m).
Board Change • Mar 28No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Board Change • Feb 12No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Price Target Changed • Dec 27Price target decreased by 24% to €12.45Down from €16.30, the current price target is an average from 2 analysts. New target price is 183% above last closing price of €4.40. Stock is up 47% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €2.24 last year.
Board Change • Dec 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman of Advisory Board Bruce Linton is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Price Target Changed • Nov 20Price target decreased by 24% to €12.45Down from €16.30, the current price target is an average from 2 analysts. New target price is 123% above last closing price of €5.58. Stock is up 89% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €2.24 last year.
Board Change • Nov 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Chairman of Advisory Board Bruce Linton was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Aug 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.9m free cash flow). Earnings have declined by 49% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Revenue is less than US$5m (€4.1m revenue, or US$4.5m). Market cap is less than US$100m (€31.6m market cap, or US$35.1m).
お知らせ • Aug 15SynBiotic SE, Annual General Meeting, Sep 20, 2024SynBiotic SE, Annual General Meeting, Sep 20, 2024, at 10:00 W. Europe Standard Time.
New Risk • Aug 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (€34.5m market cap, or US$37.9m).
New Risk • Jul 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Market cap is less than US$100m (€37.7m market cap, or US$40.4m).
New Risk • Jun 21New major risk - Revenue and earnings growthRevenue has declined by 9.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 9.9% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (€35.6m market cap, or US$38.0m).
New Risk • Mar 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (31% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€400k net loss in 2 years). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (€35.8m market cap, or US$39.2m).
Board Change • Oct 11No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (4 non-independent directors). Chairman of the Board of Directors Sebastian Stietzel is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
New Risk • Jul 02New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Minor Risks Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (€21.1m market cap, or US$23.0m).
Breakeven Date Change • May 31No longer forecast to breakevenThe analyst covering SynBiotic no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €50.0k in 2023. New forecast suggests the company will make a loss of €2.10m in 2023.
Price Target Changed • Apr 13Price target increased by 28% to €75.00Up from €58.50, the current price target is provided by 1 analyst. New target price is 859% above last closing price of €7.82. Stock is down 58% over the past year. The company is forecast to post a net loss per share of €0.19 next year compared to a net loss per share of €4.15 last year.
お知らせ • Nov 25SynBiotic SE Appoints Bruce Linton as Chairman of Newly Created Advisory BoardSynBiotic SE, accelerates implementation of the operational platform to achieve market leadership in the upcoming national legalization of recreational cannabis by securing Bruce Linton to its team. Mr. Linton is one of the most experienced and most successful cannabis entrepreneurs and investors globally and has been the driving force behind the creation of multiple global multi-billion dollar cannabis enterprises, several of them listed on NYSE, Nasdaq, TSX, TSX:V, CSE and ASX. Most notably, Mr. Linton is the founder and former Chairman and CEO of the global cannabis company Canopy Growth Corporation, which, at the time of his departure, had a market valuation of approximately CAD 20 billion and more than 25% market share in the Canadian recreational market while also being a global top tier supplier. Canopy was the first North American supplier to the German medical cannabis market. Combining unparalleled expertise in the areas of both medical and recreational cannabis, Mr. Linton is a powerful asset given SynBiotic's expansion plans, which cover both segments. Mr. Linton has been appointed as Chairman of SynBiotic's newly created Advisory Board and has invested capital in the company's most recent financing round. His investment plus options to buy further shares from existing shareholders will bring him to an ownership of approx. 5% in SynBiotic.
Board Change • Nov 17No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Sep 02SynBiotic SE Launches Full-Line Medical Cannabis BrandSynBiotic SE launches full-line medical cannabis brand. In mid-September, the pharmacy market is due to attend Expopharm, the most important leading European trade fair. SynBiotic SE will present its new brand Hempamed Rx at its own booth. Europe's largest listed corporate group in the hemp and cannabis sector is launching an extensive range of full-spectrum extracts, dronabinol and various flowers. In this process, canna.sales GmbH becomes SynBiotic Sales GmbH, with a fifteen-person field sales team consisting of employees with many years of experience in the field of medical cannabis, and GECA Pharma GmbH, responsible for the import and distribution of medical cannabis products, becomes SynBiotic Distribution GmbH. Sales offensive in the field of medical cannabis: While other cannabis companies are downsizing their sales teams and seemingly fully concentrate on the legalization of recreational use, are keeping a firm eye on all areas of the existing and future cannabis market," says Lars Müller, CEO of SynBiotic SE. The goal: to provide competent advice throughout Germany. With the sales offensive, the Munich-based corporate group wants to underline its clear vision in the wake of increasing treatments and prescriptions for medical cannabis. Products from this area can be used to treat chronic pain, among other things. In particular, patients suffering from depression and anxiety/sleep disorders, but also Tourette's, MS or epilepsy, can alleviate their symptoms and the resulting pain through the use of medical cannabis. Strong pipeline: Unprecedented product innovations: SynBiotic SE will build up further capacities in the important field of medical cannabis and further expand its dominant position not only on the distribution side. The launch of Hempamed Rx also culminates years of research and development of innovative products that will be launched under the new brand in the coming weeks and months. Particularly in the field of medical cannabis, it is important to enable treatments that are optimally adapted to individual complaints. The dosage forms in particular make an important contribution to this. In order to enable everyone to benefit from the advantages of medical cannabis, SynBiotic SE is constantly expanding its product portfolio through the use of various carrier substances. The high bio-availability is as much in focus as the good tolerability of the products.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Breakeven Date Change • Aug 27Forecast to breakeven in 2022The analyst covering SynBiotic expects the company to break even for the first time. New forecast suggests the company will make a profit of €1.70m in 2022. Average annual earnings growth of 93% is required to achieve expected profit on schedule.
Is New 90 Day High Low • Jan 11New 90-day high: €25.60The company is up 51% from its price of €17.00 on 13 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Dec 03New 90-day high: €20.20The company is up 13% from its price of €17.90 on 04 September 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
Is New 90 Day High Low • Nov 03New 90-day low: €13.90The company is down 15% from its price of €16.40 on 04 August 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period.
Is New 90 Day High Low • Oct 08New 90-day low: €14.10The company is down 21% from its price of €17.90 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 8.0% over the same period.
お知らせ • Oct 08SynBiotic SE (DUSE:L3D) acquired 25% stake in GreenLight Pharmaceuticals Ltd.SynBiotic SE (DUSE:L3D) acquired 25% stake in GreenLight Pharmaceuticals Ltd on October 6, 2020. In addition to the acquired share, SynBiotic also receives the option to strengthen its commitment in the future through further shares. SynBiotic SE (DUSE:L3D) completed the acquisition of 25% stake in GreenLight Pharmaceuticals Ltd on October 6, 2020.
お知らせ • Sep 22SynBiotic SE (DUSE:L3D) entered into an agreement to acquire BioCBD E-commerce business of Umtr Group LimitedSynBiotic SE (DUSE:L3D) entered into an agreement to acquire BioCBD E-commerce business of Umtr Group Limited on September 21, 2020. Under the terms of transaction, certain tangible and intangible assets as well as the Umtr Group's customer base relating to BioCBD e-commerce are to be taken over by SynBiotic SE. The purchase price is to be paid partly in cash and partly in cash or in shares and comprises a total of a low single-digit million amount. Major part of purchase price can be paid in exchange for shares of SynBiotic.